Overview

Adjuvant PIPAC in Gastric Cancer Patients

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
In this study patients will be offered intraperitoneal atomized chemotherapy as a supplement to the standard treatment of high-risk gastric cancer (laparoscopic removal of the stomach). Two commercially available oncologic drugs will be used (doxorubicin and cisplatin).
Phase:
Phase 1
Details
Lead Sponsor:
Michael Bau Mortensen
Treatments:
Cisplatin
Doxorubicin
Liposomal doxorubicin